Late last year, its top 20 shareholders demanded that bosses consider spinning off the company’s orthopaedics business, which makes replacement hip and knee joints.
Mr Nath said more than 60% of the company’s revenue growth last year came from products launched in the last five years.
That came after a profit warning in October, when bosses complained of poor sales in China, which had resulted in the company’s distributors sitting on unusually high levels of unsold products.
Since the profit warning, revenues for the final three months of 2024 jumped 7.8%, helping push Smith & Nephew to a 657 million dollar (£520 million) profit.
Smith & Nephew’s business lines include orthopaedics, where it makes high-tech knee and hip implants used to replace damaged or worn joints.
-Selina-Cadell-(Gonzalo)-Tim-Steed-(Antonio)--Credit-Marc-Br.jpeg?trim=106,0,107,0&quality=75&auto=webp&width=1000)
